Multiplex Immunoassay Approaches Using Luminex® xMAP® Technology for the Study of COVID-19 Disease

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been one of the most severe outbreaks of respiratory illness in history. The clinical symptoms of COVID-19 may be similar to flu, although they can be life-threatening, particularly in the elderly and immunocompromised population. Together with nucleic acid detection, serological testing has been essential for the diagnosis of SARS-CoV-2 infection but has been critically important for studying the epidemiology, serosurveillance, and for vaccine research and development. Multiplexed immunoassay technologies have a particular advantage as they can simultaneously measure multiple analytes from a single sample. xMAP technology is a multiplex analysis platform that can measure up to 500 analytes at the same time from the same sample. It has been shown to be an important tool for studying immune response to the various SARS-CoV-2 antigens, as well as for measuring host protein biomarker levels as prognostic indicators of COVID-19. In this chapter, we describe several key studies where xMAP technology was used for multiplexed analysis of SARS-COV-2 antibody responses and host protein expression in COVID-19 patients.